NovoCure stock reports 15.6 percent Q2 revenue growth
Published on 09/24/2026 at 23:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
NovoCure stock was trading at USD 16.20 on Nasdaq on September 24, 2026, with a daily change of -0.31 percent, while second-quarter revenue rose 15.6 percent to USD 183.58 million. The company also confirmed the retirement of director Timothy Scannell effective September 2, 2026, according to Stock Titan.
Q2 revenue clears consensus
The revenue result exceeded the USD 172.44 million consensus estimate by USD 11.14 million, or 6.5 percent. MarketBeat reported that adjusted Q2 EPS was a loss of USD 0.13, better than the expected loss of USD 0.33 and improved from a loss of USD 0.36 in the same quarter of 2025.
The comparison matters because revenue growth and cost discipline are moving in the same direction, even though the company remains loss-making on a GAAP basis. The adjusted EPS improvement was USD 0.20 against consensus, giving the quarter a clearer operational signal than the headline loss alone.
Cash flow turns positive
In Q2 2026, NovoCure reported operating profit of negative USD 10.562 million, consolidated net loss of USD 15.658 million and an operating margin of negative 6 percent. Operating cash flow reached USD 8.132 million, compared with negative USD 13.517 million in Q1 2026.
That sequential cash-flow swing of USD 21.649 million is the most important counterweight to the GAAP loss. It suggests that the revenue increase is beginning to support liquidity, while the negative operating margin keeps profitability as the central financial test.
Growth plan targets break-even
At the September 14, 2026, Morgan Stanley healthcare conference, management outlined a path toward adjusted EBITDA break-even by year-end 2026. Investing.com reported 8 percent year-over-year volume growth in the glioblastoma franchise, alongside expansion in pancreatic and lung cancer indications.
The strategy therefore combines a measurable existing-business gain with future launch execution. Japan is already the companys fourth-largest market, while Optune Pax expansion and broader use of Tumor Treating Fields could determine whether revenue growth becomes durable earnings growth.
Nasdaq quote stays at USD 16.20
NovoCure had a market capitalization of USD 1,886,422,608 on September 24, 2026. The stock stood at USD 16.20 on Nasdaq on that date, down USD 0.05 from the previous close of USD 16.25.
NovoCure stock facts
- Company: Novocure Ltd
- Ticker: NVCR
- Trading venue: Nasdaq
- Price as of September 24, 2026: USD 16.20
- Market capitalization: USD 1,886,422,608 as of September 24, 2026
- 52-week range: USD 9.82-21.45 as of September 24, 2026
- Sector / Industry: Healthcare / Medical Devices
